卡格列肽 Cagrilintide
理化性质
1415456-99-3
作用与功效
长效胰淀素（Amylin）受体激动剂：模拟餐后胰淀素作用，激活胰淀素受体（CTR/RAMP 复合物），强效抑制食欲、延缓胃排空，与 GLP-1 通路互补
功效：长效胰淀素受体激动剂；强效控食欲、降糖减重，同司美格鲁肽联用减重效果极强；处方药，国内仅临床阶段，私自分装流通违法。
英文详细资料 / Details (EN)
Cagrilintide is a long-acting analogue of amylin. It is being tested to treat obesity and type 2 diabetes by itself and in combination with semaglutide as cagrilintide/semaglutide ("CagriSema").
Source: English Wikipedia, "Cagrilintide".
A systematic review and metanalysis of cagrisema, published in 2024, found that cagrisema may provide weight loss benefits.
Novo Nordisk announced late at the 2025 European Association for the Study of Diabetes (EASD) annual meeting that in the REDEFINE 1 study, cagrilintide provided clinically significant weight loss, with a mean reduction in body weight of 11.8% compared to 2.3% with placebo after 68 weeks, considering adherence of all participants to treatment. In addition, approximately 1 in 3 participants (31.6%) who received cagrilintide achieved a weight loss ≥15%, compared to approximately 1 in 20 participants (4.7%) who received placebo.
^ Dutta D, Nagendra L, Harish BG, Sharma M, Joshi A, Hathur B, et al. (2024). "Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis". Indian Journal of Endocrinology and Metabolism. 28 (5): 436–444. doi:10.4103/ijem.ijem_45_24. PMC 11642503. PMID 39676787.
^ "REDEFINE 1". ^ Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Lehmann EW, Pietiläinen KH, et al. (2025). "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity". New England Journal of Medicine. 393 (7): 635–647. doi:10.1056/NEJMoa2502081. PMID 40544433.
功效：长效胰淀素受体激动剂；强效控食欲、降糖减重，同司美格鲁肽联用减重效果极强；处方药，国内仅临床阶段，私自分装流通违法。